January 2018, Volume 4, Issue 1

January 2018

Volume 4, Issue 1

This issue features a look at the misconceptions that challenge the viability of the blood-banking system, highlights from the 2017 ASH Annual Meeting, and more.

Table of Contents

January 2018 Issue

Notes From the Hill

Monday, January 1st, 2018
The American Society of Hematology (ASH) has selected Catherine Zander, PhD, to participate in the new ASH Congressional Fellowship program. The program aims to...

CROs: A Universal Problem

Monday, January 1st, 2018
Contract research organizations (CROs), which are used by much of the pharmaceutical industry to outsource research regulatory requirements, should be the epitomes of high-quality...

Hugging It Out

Monday, January 1st, 2018
Patient zero is an active and charming older widow, measuring approximately 4’11 and weighing in at 90 pounds, who wisely moved to the dry...

January 2018 Issue

National Academy of Medicine Announces New Hematology/Oncology Members, Winship Cancer Institute Earns NCI Designation,...

Monday, January 1st, 2018
Emory University’s Winship Cancer Institute Earns NCI Designation Winship Cancer Institute of Emory University in Atlanta, Georgia, was granted comprehensive cancer center designation by the...

ASH Announces 2018 Scholar Award Recipients, New Ambassador Program, and more

Monday, January 1st, 2018
Introducing the ASH Ambassador Program The ASH Ambassador Program supports recruitment and retention of trainees to hematology and to the Society, particularly underrepresented minorities, through...

January 2018 Issue

Blood Donation: Separating Myth From Fact

Monday, January 1st, 2018
After natural disasters and other tragic events, many people try to help by rushing to the nearest blood donation center. While there’s no denying...
Gary Gilliland, MD, PhD, on a camping trip to Denali National Park in Alaska.

Pulling Back the Curtain: Gary Gilliland, MD, PhD

Monday, January 1st, 2018
In this edition, Gary Gilliland, MD, PhD, talks about the detours in his path to academic medicine, the patient that inspired him to pursue...

January 2018 Issue

How would you treat a pregnant patient with type 2A von Willebrand disease?

Monday, January 1st, 2018
This month Margaret V. Ragni, MD, MPH, discusses treatment options for a pregnant patient with type 2A von Willebrand disease. And don't forget to check out...

January 2018 Issue

Can Electronic Alerts Improve VTE Prophylaxis Delivery?

Monday, January 1st, 2018
The use of thromboprophylaxis among hospitalized patients at risk for a venous thromboembolism (VTE) – a major complication of hospitalization – remains inconsistent. Both...

Delaying Treatment Reduces Survival Benefits of Antifibrinolytics in Patients With Acute Severe Bleeding

Monday, January 1st, 2018
Administration of antifibrinolytic agents, such as tranexamic acid, reduces patients’ risk of death from trauma-related or postpartum bleeding, but delaying time to treatment for...

HCT Outcomes in Patients With Autoimmune Diseases Vary With Location, Treatment Center Volume

Monday, January 1st, 2018
Hematopoietic cell transplantation (HCT) has been evaluated as a treatment option for patients with autoimmune diseases (ADs) that respond poorly to conventional immunosuppressive treatments...
WIB_icon

The TRUTH About Ruxolitinib in Thalassemia: Lower Transfusion Burden, No Improvement in Hemoglobin

Monday, January 1st, 2018
In an update from the phase IIa TRUTH study evaluating ruxolitinib in patients with transfusion-dependent thalassemia, investigators reported that treatment with the JAK1/2 inhibitor...
WIB_icon

Early Phase Study of Selinexor With and Without Dexamethasone for Patients With Myeloma and...

Monday, January 1st, 2018
According to results of a phase I study published in Blood, treatment with the XPO1 inhibitor selinexor and dexamethasone led to half of patients...

Emicizumab-kxwh Approved by FDA for Patients With Hemophilia A and Inhibitors

Monday, January 1st, 2018
The U.S. Food and Drug Administration approved the first-in-class emicizumab-kxwh for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult...

FDA Approves Obinutuzumab for Frontline Treatment of Patients With Follicular Lymphoma

Monday, January 1st, 2018
The U.S. Food and Drug Administration approved obinutuzumab in combination with chemotherapy, followed by obinutuzumab alone, for the firstline treatment of patients with stage...

FDA Expands Approval of Dasatinib for Pediatric Patients With CP-CML

Monday, January 1st, 2018
The U.S. Food and Drug Administration expanded the indication of the tyrosine kinase inhibitor dasatinib to include pediatric patients with Philadelphia chromosome–positive (Ph+) chronic-phase...

Vemurafenib Receives FDA Approval for Treatment of Rare Erdheim-Chester Disease

Monday, January 1st, 2018
The U.S. Food and Drug Administration expanded the approval of the kinase inhibitor vemurafenib to include adults with Erdheim-Chester disease (ECD) and the BRAF...

FDA Okays Complete Blood Cell Count Test

Monday, January 1st, 2018
The U.S. Food and Drug Administration (FDA) cleared the XW-100 Automated Hematology Analyzer, a complete blood cell count (CBC) test that can be used...

BCMA Antibody-Drug Conjugate Receives Breakthrough-Therapy Designation for Myeloma

Monday, January 1st, 2018
The U.S. Food and Drug Administration (FDA) granted breakthrough-therapy designation to the B-cell maturation antigen antibody-drug conjugate GSK2857916 for relapsed/refractory multiple myeloma (MM). The...

FDA Grants Accelerated Approval to Acalabrutinib for Mantle Cell Lymphoma

Monday, January 1st, 2018
The U.S. Food and Drug Administration granted accelerated approval to the kinase inhibitor acalabrutinib for adults with previously treated mantle cell lymphoma (MCL). The approval...

FDA Approves Lower Dose of Rivaroxaban for Recurrent VTE

Monday, January 1st, 2018
The U.S. Food and Drug Administration approved 10 mg once-daily dosing for rivaroxaban to prevent recurrent venous thromboembolism (VTE) after at least six months...

Patients With CLL Willing to Trade Treatment Efficacy for Reduced Costs and Adverse Events

Monday, January 1st, 2018
Some patients living with chronic lymphocytic leukemia (CLL) are willing to accept drugs that are less effective in exchange for reduced adverse events (AEs)...

CD22: A New Target for CAR T-Cell Therapy in Patients With B-ALL?

Monday, January 1st, 2018
The revolutionary chimeric antigen receptor (CAR) T-cell therapies that gained approval from the U.S. Food and Drug Administration in 2017 both target CD19; the...

January 2018 Issue

Interim Results from the First-in-Human Trial of Antibody Drug Conjugate ADCT-402 in B-Cell Malignancies

Monday, January 1st, 2018
In a first-in-human trial of loncastuximab tesirine, the CD19-targeting antibody drug conjugate (ADC) appeared to have manageable toxicity and encouraging efficacy as a single...

Phase I Trial Shows “Exciting” Results With Avapritinib in Advanced Systemic Mastocytosis

Monday, January 1st, 2018
The oral KIT D816V inhibitor avapritinib (formerly known as BLU-285) could provide an alternative treatment option for patients with advanced systemic mastocytosis (SM), including...

Transfusion Dependence Delays Hospice Enrollment in Patients With Leukemia

Monday, January 1st, 2018
Because many hospice organizations disallow life-extending transfusion support, transfusion dependence (TD) can pose a substantial barrier to enrolling patients with leukemia in palliative or...

ZUMA-1 at One Year: Durable Responses to Axicabtagene Ciloleucel in Patients With Aggressive NHL

Monday, January 1st, 2018
In October 2017, axicabtagene ciloleucel became the second chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration, and the...

No Survival Benefit With Adding Rituximab to Ibrutinib in Patients With Chronic Lymphocytic Leukemia

Monday, January 1st, 2018
In a randomized, open-label, single-center, phase II study, researchers found that the addition of rituximab to ibrutinib did not improve progression-free survival (PFS; primary...
Stephen J. Schuster, MD, speaks at a press briefing.

Tisagenlecleucel Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell...

Monday, January 1st, 2018
Updated results from the phase II JULIET trial of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) presented at the 2017 ASH...

Improving Pain Management in Patients With Sickle Cell Disease

Monday, January 1st, 2018
Sickle cell disease (SCD) is associated with debilitating acute and chronic pain that can occur without warning, frequently sending people to the emergency department...

First Successful Gene Therapy Performed for Hemophilia A

Monday, January 1st, 2018
In an ongoing phase I/II study of patients with hemophilia A, those who received a single infusion of BMN 270 (an adeno-associated virus serotype...

Could Daratumumab Be the First Frontline Monoclonal Antibody for Newly Diagnosed Myeloma?

Monday, January 1st, 2018
Results from the first randomized, phase III trial to evaluate frontline use of a monoclonal antibody in transplant-ineligible patients with newly diagnosed multiple myeloma...

Salvage Regimen of Pomalidomide, Cyclophosphamide, and Dexamethasone Has High Response Rates in Lenalidomide-Refractory Myeloma...

Monday, January 1st, 2018
Eighty-five percent of patients with relapsed/refractory multiple myeloma (MM) achieved a partial remission (PR) or better (primary endpoint) when cyclophosphamide was added to pomalidomide...

SHARE